Prospective evaluation of ADAMTS-13, von Willebrand factor and Interleukin-6 in vascular surgery

• Conditions: M31.1; Thrombotic microangiopathy

• Registration Number: DRKS00020821
• Lead Sponsor: Hämophiliezentrum, Institut für Transfusionsmedizin, Medizinische Klinik III, Goethe Universitätsklinikum

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Completion: 2017-04-11
• Study Start: 2020-03-03
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 93

Inclusion Criteria

1. Patient information and written informed consent

2. Age of majority (=>18 years)

3. patients of the Clinic for Vascular and Endovascular surgery undergoing one of the following procedures: Carotid TEA, Femoral TEA/bypass grafting of the lower extremity, EVAR, open aortic surgery

Exclusion Criteria

1. missing patient information or informed consent

2. known TTP in medical history

3. current pregnancy

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Kinetics of ADAMTS-13 activity in time course by blood sampling (5 time points: pre-, intra-(60 and 120 min post incision), postoperativ (2 d and 4 d post surgery).

Secondary Outcome Measures

Name	Time	Method
Blood sampling. Determination at 5 time points [pre, intra (60, 120 min), postoperative (2d, 4d post surgery)]: platelet number, vWF-multimeres, vWF-Antigen, vWF-activity und lactate Dehydrogenase (LDH), fibrinogen, INR, PTT, FVIII, FXIII - <br>- angiogenetic parameters like HIF-1-alpha, VEGF, VEGFR1, VEGFR2, angiopoetin, Interleukin-6, Interleukin-8 <br>Determination at 2 time points : preoperativ, 2d post surgery:<br>-platelet function regarding ASS resistances<br><br>Additional documentation of:<br>ADAMTS13 inhibitor, intraoperative <br>volume substitution (Erythrozyte concentrate und FFP)